Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock Has Consensus Target Price of $189.88 According to Analysts

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have been assigned an average rating of “Moderate Buy” from the fourteen analysts that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $189.88.

Several analysts have recently weighed in on the stock. Citizens Jmp upgraded shares of Quince Therapeutics from a “market perform” rating to an “outperform” rating and set a $77.00 price objective on the stock in a research report on Tuesday, September 22nd. Rodman & Renshaw initiated coverage on Quince Therapeutics in a research report on Thursday, September 24th. They set a “buy” rating and a $70.00 price target on the stock. Citigroup restated a “market outperform” rating on shares of Quince Therapeutics in a research report on Tuesday, September 29th. Leerink Partners initiated coverage on Quince Therapeutics in a report on Wednesday, June 24th. They issued an “outperform” rating and a $80.00 price objective for the company. Finally, Wall Street Zen lowered Quince Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 22nd.

Institutional Trading of Quince Therapeutics

An institutional investor recently bought a new stake in Quince Therapeutics stock. 683 Capital Management LLC bought a new position in Quince Therapeutics, Inc. (NASDAQ:QNCX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 238,177 shares of the company’s stock, valued at approximately $798,000. 683 Capital Management LLC owned approximately 0.43% of Quince Therapeutics at the end of the most recent reporting period. 30.75% of the stock is owned by hedge funds and other institutional investors.

Quince Therapeutics Price Performance

Shares of QNCX opened at $32.01 on Wednesday. Quince Therapeutics has a 1-year low of $15.10 and a 1-year high of $909.98. The company has a market capitalization of $32.65 million, a P/E ratio of -0.20 and a beta of 1.33. The firm’s 50 day simple moving average is $30.80 and its 200 day simple moving average is $24.88.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings results on Friday, August 14th. The company reported ($12.31) EPS for the quarter, topping analysts’ consensus estimates of ($28.02) by $15.71. On average, equities analysts anticipate that Quince Therapeutics will post -8.39 earnings per share for the current year.

About Quince Therapeutics

Quince Therapeutics, Inc (NASDAQ:QNCX) is a clinical-stage biotechnology company developing therapies for rare and debilitating diseases. The company focuses on precision medicines designed to address underlying disease mechanisms and unmet medical needs in patient populations that may have limited treatment options.

Quince’s pipeline includes efzofitimod, an investigational immunomodulator being developed for pulmonary sarcoidosis, a rare inflammatory disease that can affect lung function.